Skip to content

Study · Randomized controlled trial · n = 100 · 2005

3 results

Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery.

Ozal E, Kuralay E, Yildirim V, Kilic S, Bolcal C, Kücükarslan N, Günay C, Demirkilic U, Tatar H

The Annals of thoracic surgery1 May 2005Cited by 133 (Europe PMC)

PMID15854942 (opens in a new tab)DOI10.1016/j.athoracsur.2004.10.038 (opens in a new tab)PepBankPUB-15854942
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In high-risk cardiac surgery patients, methylene blue reduced vasoplegic syndrome incidence versus controls.

    In plain wordsIn high-risk cardiac surgery patients, methylene blue reduced vasoplegia compared with controls.

    Peptide
    Methylene blue
    Outcome
    DecreaseVasoplegic syndrome incidence
    Study

    n = 100

    Comparator
    No methylene blue
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    2 mg/kg · intravenousAs given in this study (human).

    Measurements

    Vasoplegic syndrome incidence
    0%
    methylene blue group, 0 of 50
    Vasoplegic syndrome incidence
    26%
    control group, 13 of 50

    Source sentences

    Summary
    Although similar in terms of all demographic and operative variables, the two groups differed significantly in terms of vasoplegic syndrome incidence (0% in group 1[0 of 50] vs 26% in group 2 [13 of 50]; p < 0.001).
    2 context sentences
    Summary · context
    One hundred patients scheduled for coronary artery bypass graft surgery who were at high risk for vasoplegia because they were preoperatively using angiotensin-converting enzyme inhibitors, calcium channel blockers, and heparin were randomly assigned
    Summary · context
    Methylene blue (1% solution) was administered intravenously at a dose of 2 mg/kg for more than 30 minutes, beginning in the intensive care unit 1 hour before surgery.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In high-risk cardiac surgery patients, methylene blue shortened intensive care unit stay versus controls.

    In plain wordsIn high-risk cardiac surgery patients, methylene blue shortened intensive care stays compared with controls.

    Peptide
    Methylene blue
    Outcome
    DecreaseIntensive care unit stay
    Study

    n = 100

    Comparator
    No methylene blue
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    2 mg/kg · intravenousAs given in this study (human).

    Measurements

    Mean intensive care unit stay
    1.2 days
    methylene blue group, SD 0.5
    Mean intensive care unit stay
    2.1 days
    control group, SD 1.2

    Source sentences

    Summary
    The two study groups also differed significantly in terms of average intensive care unit stay (1.2 +/- 0.5 days in group 1 vs 2.1 +/- 1.2 days in group 2; p < 0.001)
    2 context sentences
    Summary · context
    One hundred patients scheduled for coronary artery bypass graft surgery who were at high risk for vasoplegia because they were preoperatively using angiotensin-converting enzyme inhibitors, calcium channel blockers, and heparin were randomly assigned
    Summary · context
    Methylene blue (1% solution) was administered intravenously at a dose of 2 mg/kg for more than 30 minutes, beginning in the intensive care unit 1 hour before surgery.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In high-risk cardiac surgery patients, methylene blue shortened hospital stay versus controls.

    In plain wordsIn high-risk cardiac surgery patients, methylene blue shortened hospital stays compared with controls.

    Peptide
    Methylene blue
    Outcome
    DecreaseHospital stay
    Study

    n = 100

    Comparator
    No methylene blue
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    2 mg/kg · intravenousAs given in this study (human).

    Measurements

    Mean hospital stay
    6.1 days
    methylene blue group, SD 1.7
    Mean hospital stay
    8.4 days
    control group, SD 2.0

    Source sentences

    Summary
    and average hospital stay (6.1 +/- 1.7 days in group 1 vs 8.4 +/- 2.0 days in group 2; p < 0.001).
    2 context sentences
    Summary · context
    One hundred patients scheduled for coronary artery bypass graft surgery who were at high risk for vasoplegia because they were preoperatively using angiotensin-converting enzyme inhibitors, calcium channel blockers, and heparin were randomly assigned
    Summary · context
    Methylene blue (1% solution) was administered intravenously at a dose of 2 mg/kg for more than 30 minutes, beginning in the intensive care unit 1 hour before surgery.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.